The company’s financial targets remain in place, but have been delayed in relation to previous announcements, due to the need to perform optimization studies. The company expects to receive the first revenues from self-pay sales in Q3 2020.
- Immunovia’s targets to achieve a turnover of SEK 250-300 million in 2022 based on self-pay for IMMray™ PanCan-d
- Immunovia targets further to achieve a total turnover, for self-pay and reimbursement, of SEK 800-1,000 million in 2024.
Immunovia’s financial targets set forth above constitute forward-looking information and are based on a number of assumptions about the environment in which the Company operates, which may vary significantly and deteriorate over time from what Immunovia assessed when the financial targets were adopted. As a consequence, Immunovia’s ability to achieve the financial targets consists of uncertainties and contingencies, some of which are outside the Company’s control. There is no guarantee that Immunovia can achieve the financial targets or that Immunovia’s financial position or operating profit will not differ materially from the financial targets.